Safety and tolerability of testosterone patch therapy for up to 4 years in surgically menopausal women receiving oral or transdermal oestrogen

References

• ShifrenJL, BraunsteinGD, SimonJA, CassonPR, BusterJE, RedmondGP, BurkiRE, GinsburgES, RosenRC, LeiblumSR, et al. Transdermal testosterone treatment in women with impaired sexual function after oophorectomy. N Engl J Med 2000;343:682–688.
   PubMed Web of Science ®Google Scholar
• GoldstatR, BrigantiE, TranJ, WolfeR, DavisSR. Transdermal testosterone therapy improves well-being, mood, and sexual function in premenopausal women. Menopause 2003;10:390–398.
   PubMed Web of Science ®Google Scholar
• LingS, KomesaroffPA, SudhirK. Cardiovascular physiology of androgens and androgen testosterone therapy in postmenopausal women. Endocr Metab Immune Disord Drug Targets 2009;9:29–37.
   Google Scholar
• WattsNB, NotelovitzM, TimmonsMC, AddisonWA, WiitaB, DowneyLJ. Comparison of oral estrogens and estrogens plus androgen on bone mineral density, menopausal symptoms, and lipid-lipoprotein profiles in surgical menopause. Obstet Gynecol 1995;85:529–537.
   PubMed Web of Science ®Google Scholar
• DavisSR, McCloudP, StraussBJ, BurgerH. Testosterone enhances estradiol's effects on postmenopausal bone density and sexuality. Maturitas 1994;21:227–236.
   Google Scholar
• SimonJ, BraunsteinG, NachtigallL, UtianW, KatzM, MillerS, Waldbaum A, Bouchard C, Derzko C, Buch A. Testosterone patch increases sexual activity and desire in surgically menopausal women with hypoactive sexual desire disorder. J Clin Endocrinol Metab 2005;90:5226–5233.
   PubMed Web of Science ®Google Scholar
• BusterJE, KingsbergSA, AguirreO, BrownC, BreauxJG, BuchA, Rodenberg CA, Wekselman K, Casson P. Testosterone patch for low sexual desire in surgically menopausal women: a randomized trial. Obstet Gynecol 2005;105:944–952.
   PubMed Web of Science ®Google Scholar
• ShifrenJL, BraunsteinGD, SimonJA, CassonPR, BusterJE, RedmondGP, Burki RE, Ginsburg ES, Rosen RC, LeiblumSR. Transdermal testosterone treatment in women with impaired sexual function after oophorectomy. N Engl J Med 2000;343:682–688.
   PubMed Web of Science ®Google Scholar
• BraunsteinGD, SundwallDA, KatzM, ShifrenJL, BusterJE, SimonJA, Bachman G, Aguirre O, Lucas JD, Rodenberg CA. Safety and efficacy of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women: a randomized, placebo-controlled trial. Arch Intern Med 2005;165:1582–1589.
   PubMed Web of Science ®Google Scholar
• DavisSR, van der MoorenMJ, van LunsenRH, LopesP, RibotC, ReesM, Moufarege A, Rodenberg C, Buch A, Purdie PW. Efficacy and safety of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women: a randomized, placebo-controlled trial. Menopause 2006;13:387–396.
   PubMed Web of Science ®Google Scholar
• ShifrenJL, DavisSR, MoreauM, WaldbaumA, BouchardC, Derogatis L, Derzko C, Bearnson P, Kakos N, O'Neill S. Testosterone patch for the treatment of hypoactive sexual desire disorder in naturally menopausal women: results from the Intimate NM1 study. Menopause 2006;143:770–779.
   Google Scholar
• LorenzoEM. Familial study of hirsutism. J Clin Endocrinol 1970;31:556–564.
   PubMed Web of Science ®Google Scholar
• PalatsiR, HirvensaloE, LiukkoP, MalmiharjuT, MattilaL, RiihiluomaP, Ylöstalo P. Serum total and unbound testosterone and sex hormone binding globulin (SHBG) in female acne patients treatment with two different oral contraceptives. Acta Derm Vernereol (Stockh) 1984;64:517–523.
   PubMed Web of Science ®Google Scholar
• RossouwJE, AndersonGL, PrenticeRL, LaCroixAZ, KooperbergC, StefanickML, Jackson RD, Beresford SA, Howard BV, Johnson KC. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: prinicpal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321–333.
   PubMed Web of Science ®Google Scholar
• http://seer.cancer.gov, Age-Specific SEER Incidence Rates, 2002–2006; Access Date: 09OCT2009
   Google Scholar
• SprattJS, MeyerJS, SprattJA. Rates of growth of human solid neoplasms: part I. J Surg Oncol 1995;60,137–146.
   PubMed Web of Science ®Google Scholar
• TamimiRM, HankinsonSE, ChenWY, RosnerB, ColditzGA. Combined estrogen and testosterone use and risk of breast cancer in postmenopausal women. Arch Intern Med 2006;166:1483–1489.
   PubMed Web of Science ®Google Scholar
• BrintonLA, HooverR, FraumeniJF Jr. Menopausal oestrogens and breast cancer risk: an expanded case-control study. Br J Cancer 1986;54:825–832.
   PubMed Web of Science ®Google Scholar
• EwertzM. Influence of non-contraceptive exogenous and endogenous sex hormones on breast cancer risk in Denmark. Int J Cancer 1988;42:832–838.
   PubMed Web of Science ®Google Scholar
• DimitrakakisC, JonesRA, LiuA, BondyCA. Breast cancer incidence in postmenopausal women using testosterone in addition to usual hormone therapy. Menopause 2004;11:531–535.
   PubMed Web of Science ®Google Scholar
• ColditzGA, HankinsonSE, HunterDJ, WillettWC, MansonJE, StampferMJ, Hennekens C, Rosner B, Speizer FE. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med 1995;332:1589–1593.
   PubMed Web of Science ®Google Scholar
• BerrinoF, MutiP, MicheliA, BolelliG, KroghV, SciajnoR, Pisani P, Panico S, Secreto G. Serum sex hormone levels after menopause and subsequent breast cancer. J Natl Cancer Inst 1996;88:291–296.
   PubMed Web of Science ®Google Scholar
• DorganJF, LongcopeC, StephensonHE Jr, FalkRT, MillerR, FranzC, Kahle L, Campbell WS, Tangrea JA, Schatzkin A. Relation of prediagnostic serum estrogen and androgen levels to breast cancer risk. Cancer Epidemiol Biomarkers Prev 1996;5:533–539.
   PubMed Web of Science ®Google Scholar
• KeyT, ApplebyP, BarnesI, ReevesG. Endogenous Hormones and Breast Cancer Collaborative Group. Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst 2002;94:606–616.
   PubMed Web of Science ®Google Scholar
• CauleyJA, LucasFL, KullerLH, StoneK, BrownerW, CummingsSR. Elevated serum estradiol and testosterone concentrations are associated with a high risk for breast cancer. Study of Osteoprotic Fractures Research Group. Ann Intern Med 1999;130:270–277.
   PubMed Web of Science ®Google Scholar
• HankinsonSE, WillettWC, MansonJE, ColditzGA, HunterDJ, SpiegelmanD, Barbieri RL, Speizer FE. Plasma sex steroid hormone levels and risk of breast cancer in postmenopausal women. J Natl Cancer Inst 1998;90:1292–1299.
   PubMed Web of Science ®Google Scholar
• Zeleniuch-JacquotteA, BruningPF, BonfrerJM, KoenigKL, ShoreRE, KimMY, Pasternack BS, Toniolo P. Relation of serum levels of testosterone and dehydroepiandrosterone sulfate to risk of breast cancer in postmenopausal women. Am J Epidemiol 1997;145:1030–1038.
   PubMed Web of Science ®Google Scholar
• ThomasHV, KeyTJ, AllenDS, MooreJW, DowsettM, FentimanIS, Wang DY. A prospective study of endogenous serum hormone concentrations and breast cancer risk in post-menopausal women on the island of Guernsey. Br J Cancer 1997;76:401–405.
   PubMed Web of Science ®Google Scholar
• LipworthL, AdamiHO, TrichopoulosD, CarlströmK, MantzorosC. Serum steroid hormone levels, sex hormone-binding globulin, and body mass index in the etiology of postmenopausal breast cancer. Epidemiology 1996;7:96–100.
   PubMed Web of Science ®Google Scholar
• AndoS, De AmicisF, RagoV, CarpinoA, MaggioliniM, PannoML, Lanzino M. Breast cancer: from estrogen to androgen receptor. Mol Cell Endocrinol 2002;193:121–128.
   PubMed Web of Science ®Google Scholar
• OrtmannJ, PriftiS, BohlmannMK, Rehberger-SchneiderS, StrowitzkiT, RabeT. Testosterone and 5 alpha-dihydrotestosterone inhibit in vitro growth of human breast cancer cell lines. Gynecol Endocrinol 2002;16:113–120.
   PubMed Web of Science ®Google Scholar
• DimitrakakisC, ZhouJ, WantJ, BelangerA, LaBrieF, ChengC, et al. A physiologic role for testosterone in limiting estrgenic stimulation of the breast. Menopause 2003;10:292–298.
   PubMed Web of Science ®Google Scholar
• ZhouJ, NgS, Adesanya-FamuiyaO, AndersonK, BondyCA. Testosterone inhibits estrogen-induced mammary epithelial proliferation and suppresses estrogen receptor expression. FASEB J 2000;14:1725–1730.
   PubMed Web of Science ®Google Scholar
• HoflingM, HirschbergA, SkoogL, TaniE, HagerstromT, von SchoultzB. Testosterone inhibits estrogen/progestogen-induced breast cell proliferation in postmenopausal women. Menopause 2007;14:183–190.
   PubMed Web of Science ®Google Scholar
• LandahlS, BengtssonC, SigurdssonJ, SvanborgA, SvardsuddS. Age-related changes in blood pressure. Hypertension 1986;8:1044–1049.
   PubMed Web of Science ®Google Scholar
• KuczmarskiRJ, FlegalKM, CampbellSM, JohnsonCL. Increasing prevalence of overweight among US adults: The National Health and Nutrition Examination survey 1960–1991. JAMA 1994;272:205–211.
   PubMed Web of Science ®Google Scholar
• U.S. Department of Health and Human Services. The seventh report of the joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure.
   Google Scholar
• ReevesKW, StoneRA, ModugnoF, NessRB, VogelVG, WeissfeldJL, HabelLA, SternfeldB, CauleyJA. Longitudinal association of anthropometry with mammographic breast density in the Study of Women's Health Across the Nation. Int J Cancer 2009;124:1169–1177.
   PubMed Web of Science ®Google Scholar
• BasariaS, DobbsAS. Safety and adverse effects of androgens: how to counsel patients. Mayo Clin Proc 2004;79(4 Suppl):S25–S32.
   Google Scholar
• LiuPY, DeathAK, HandelsmanDJ. Androgens and cardiovascular disease. Endocr Rev 2003;24:313–340.
   PubMed Web of Science ®Google Scholar
• WuFC, von EckardsteinA. Androgens and coronary artery disease. Endocr Rev 2003;24:183–217.
   PubMed Web of Science ®Google Scholar
• RexrodeKM, MansonJE, LeeI-M, RidkerPM, SlussPM, CookNR, BuringJE. Sex Hormone levels and risk of cardiovascular events in postmenopausal women. Circulation 2003;108:1688–1693.
   PubMed Web of Science ®Google Scholar
• LaughlinGA, GoodellV, Barrett-ConnorE. Extremes of endogenous testosterone are associated with increased risk of incident coronary events in older women. J Clin Endocrinol Metab 2010;95:740–747.
   PubMed Web of Science ®Google Scholar